Fibre diversity, the butyrate relay, and an honest line.

First, the honesty

This is the science Buta-8 is built on. We’re deliberately detailed about the mechanism and deliberately strict about proof.

The problem has two halves

Fibre is the most under-consumed nutrient in the modern diet. In the US, around 95% of adults fall short; average intake is ~16 g a day against a recommended 25–38 g. A low-fibre diet doesn’t just slow you down — it starves the gut microbiome of the fermentable material it runs on.

The second half is why people who try to fix it give up: fast-fermenting fibres (inulin, FOS, GOS) — the ones most “prebiotic” blends are built from — are a common cause of gas and bloating. A product can be scientifically sound and still fail if you quit on day four. Tolerability isn’t a footnote; it’s half the problem.

Fibre is not one thing

Different fibres do different jobs. Buta-8 is built across the functional spectrum, not on a single fibre:

• Psyllium — a viscous, gel-forming fibre; barely fermented; it bulks and softens, and moderates the fermentation of the fibres alongside it.
• Chicory inulin — fast-fermenting in the upper colon; the prebiotic workhorse, but high-gas on its own.
• Resistant potato starch — slowly fermented, further down; needs a keystone bacterium to unlock.
• Acacia — the slowest, gentlest, lowest-gas of the fermentable fibres.
• Jamun & baobab — two plant botanicals carrying polyphenols.

The three fermentable fibres are paced fast → slow across the colon, so the substrate supply is staggered rather than dumped — which is also part of why it’s gentler.

Gentle by design

Here’s the mechanism behind “gentle.” In a randomised, MRI-controlled trial, taking psyllium together with inulin produced less colonic gas than inulin alone (Gunn et al., Gut 2022): the viscous psyllium gel slows and redistributes the fermentation, so gas is produced gradually and cleared rather than building up.

Two honest notes: the effect is kinetic (it slows the rate, it doesn’t “cancel” gas), and that trial used 20 g each — far above Buta-8’s 1.45 g inulin and 2.80 g psyllium. So the mechanism is established; Buta-8 applies it at much lower doses and a more protective ratio, keeping psyllium at or above the inulin load.

How butyrate is actually made — the relay

The simple story is “fibre → bacteria → butyrate.” The real one is a relay between different bacteria:

• Primary degraders break fibre down and release acetate, the simplest short-chain fatty acid.
• Butyrate producers (Faecalibacterium prausnitzii, Roseburia) take up that acetate and turn it into butyrate — drawing 56–91% of the butyrate carbon from acetate made by other bacteria (Duncan et al., 2002, 2004).

And some fibres only work inside a functioning community: resistant starch can’t be used until a keystone degrader, Ruminococcus bromii, opens it up (Ze et al., 2012).

Why not just take a butyrate pill?

Because fermenting fibre is the body’s own way of making butyrate — produced continuously, in the distal colon, right next to the cells that use it. A butyrate capsule delivers, at best, one molecule. Fibre also yields acetate and propionate, feeds microbial diversity, and supports regularity, fullness and a gentler post-meal glucose curve. The molecule isn’t the meal.

We don’t claim Buta-8 raises butyrate more than a direct-butyrate product — we feed the body’s own continuous production while delivering everything else fibre does.

Butyrate is the fuel of the gut wall

Butyrate is the preferred energy source of the cells lining your colon — they draw up to ~70% of their energy from short-chain fatty acids, butyrate first (Roediger 1980; Donohoe et al., 2011). A fibre-poor diet doesn’t just slow transit; it under-fuels the gut wall. A well-fuelled lining maintains a tighter barrier (Peng et al., 2009). We don’t claim Buta-8 “reduces inflammation” — only that the mechanism by which fibre supports the barrier is well characterised.

The longevity link — a real mechanism, not a promise

Buta-8 is named for butyrate, and this is where we’re most careful. The honest split: the mechanism is genuinely citable; the outcome on a person is not.

What’s solid: butyrate is a textbook epigenetic regulator (an HDAC inhibitor; Candido et al., 1978), it’s studied for anti-inflammatory signalling (regulatory-T-cell induction; Furusawa et al., 2013; Arpaia et al., 2013) and mitochondrial pathways, and higher dietary fibre intake is robustly associated with lower all-cause mortality (around 7% lower per extra 8 g/day; Reynolds et al., Lancet 2019).

The plant layer

Some plant compounds act on your gut bacteria, which convert them into the active molecule — the cleanest example is ellagitannins → urolithin A, linked to mitophagy (Ryu et al., 2016; Andreux et al., 2019). Only about 40% of people produce meaningful urolithin A, and the difference is microbiome composition (Tomás-Barberán et al., 2017) — another reason diversity matters. Jamun and baobab add to the polyphenol pool; at Buta-8’s sub-gram doses we present this as a direction of travel, not a product claim.

What’s in it

Per 8 g scoop	Amount
Chicory inulin (Cichorium intybus)	1.45 g
Resistant potato starch (Solanum tuberosum)	0.96 g
Acacia / gum arabic (Acacia senegal)	1.50 g
Psyllium husk (Plantago ovata)	2.80 g
Baobab (Adansonia digitata)	0.43 g
Jamun (Syzygium cumini)	0.48 g
+ taste: erythritol + monk fruit, citric acid	0.38 g
Total	8.0 g · ≈6 g fibre

About 6 g fibre and ~15 kcal per scoop, low sugar, plant-based. Every gram disclosed — no proprietary blend.

8 g is a contribution, not a cure

Two kinds of dose-response matter. Threshold effects need a minimum dose to fire — for example, psyllium’s cholesterol effect needs ≥7 g/day on its own, which Buta-8 deliberately doesn’t deliver or claim. Cumulative effects build through the day — fibre feeding microbiome diversity and the butyrate pool. Buta-8 lives in the cumulative register: 8 g/day (~6 g fibre) is a meaningful daily contribution toward closing the fibre gap, roughly 40–65% of the typical shortfall — not a clinical monodose of any single ingredient.

What’s proven, what’s mechanism, what’s not

We tag our own claims so you don’t have to:

What the pilot will measure

An open-label daily-use pilot (target ~200, with continuous glucose monitoring): tolerability and adherence over four weeks, repurchase intent, taste, post-meal glucose, regularity and comfort, and — if feasible — faecal short-chain fatty acids on a subset. It will turn “true in general” into “observed for Buta-8.” It won’t establish clinical or longevity outcomes; those need randomised controlled trials. We’ll report it as what it is.

References

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

← Back to Buta-8